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Amniotic fluid (AF) was described as a potential source of mesenchymal stem cells (MSCs) for biomedicine purposes. Therefore,
evaluation of alternative cryoprotectants and freezing protocols capable to maintain the viability and stemness of these cells after
cooling is still needed. AF stem cells (AFSCs) were tested for diﬀerent freezing methods and cryoprotectants. Cell viability, gene
expression, surface markers, and plasticity were evaluated after thawing. AFSCs expressed undiﬀerentiated genes Oct4 and Nanog;
presented typical markers (CD29, CD44, CD90, and CD105) and were able to diﬀerentiate into mesenchymal lineages. All tested
cryoprotectants preserved the features of AFSCs however, variations in cell viability were observed. In this concern, dimethyl
sulfoxide (Me2SO) showed the best results. The freezing protocols tested did not promote significant changes in the AFSCs
viability. Time programmed and nonprogrammed freezing methods could be used for successful AFSCs cryopreservation for 6
months. Although tested cryoprotectants maintained undiﬀerentiated gene expression, typical markers, and plasticity of AFSCs,
only Me2SO and glycerol presented workable viability ratios.
1. Introduction
Knowledge about cryopreservation protocols that keep un-
changed original stem cells properties is extremely important
for cell culture and stem cells storage. For prolonged storage,
cells are usually slowly frozen and stored at −196◦C in liquid
nitrogen. Slowly cooling avoids intracellular ice buildup,
which can cause rupture of the cell membrane. Nevertheless,
it can result in dehydration of the cells by formation of extra-
cellular ice. To prevent this, an ideal cooling rate should be
chosen and a cryoprotectant added. The general properties
required for the cryoprotectant compounds are that they
have low molecular weight, are nontoxic, and have low costs
[1, 2].
Cryoprotectants are divided into two main classes: intra-
cellular agents, which penetrate inside the cells preventing
ice crystals formation and membrane rupture (i.e., dimethyl
sulfoxide (Me2SO), glycerol, and ethylene glycol) and extra-
cellular compounds that do not penetrate in cell membrane
and act by reducing the hyperosmotic eﬀect present in freez-
ing procedure. Among them are sucrose, trehalose, dextrose,
and polyvinylpyrrolidone [3].
The main commonly used cryoprotectant, dimethylsul-
foxide (Me2SO), provides a high rate of postfreezing cell sur-
vival, but several groups show that it can promote stem-cell
diﬀerentiation in neuronal lineage and also presents cyto-
toxicity at room temperature [4–8]. There are few alterna-
tive cryoprotectants to Me2SO use at the moment. Other
substances such as glycerol, sucrose, or trehalose do not
present cytotoxicity but still need to be more evaluated as
cryoprotectants for mesenchymal stem cells (MSCs).
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MSCs are multipotent cells capable to diﬀerentiate into
several lineages in vitro. They are described as adherent cells
with fibroblast-like morphology and able to diﬀerentiate
in mesenchymal lineages such as chondrogenic, osteogenic,
myogenic, and adipogenic [9]. In other studies it was dem-
onstrated that MSCs, under proper conditions, are also
capable of diﬀerentiating into nonmesenchymal lineages as
hepatocyte and neuronal-like cells [10, 11]. Human amniotic
fluid (AF), a dynamic and complex mixture that reflects
the physiological status of the developing fetus, was related
recently as an alternative source of MSCs [12].
AF obtained in second trimester of pregnancy is com-
posed of a wide variety of cells derived mainly from fetal
exfoliation during development. Among these cells, some
have adherent properties and express undiﬀerentiated mark-
ers such as Oct-4 gene. These cells are also capable of self-
renewal and diﬀerentiation into mesodermal tissues in cul-
ture. They have been classified as amniotic fluid mesenchy-
mal stem cells (AFSCs) [13–15].
Here we evaluated the eﬀects of two cryopreservation
methods (time-programmed and nonprogrammed tempera-
ture freezing) and four distinct cryoprotectants in the AFSCs
viability and main characteristics maintenance after liquid
nitrogen storage.
2. Materials andMethods
All culture media and chemical reagents were obtained from
Sigma Chemical Co. (St. Louis, MO, USA). Fetal bovine
serum and antibiotics were purchased from Invitrogen
(Carlsbad, CA, USA). Primers were from IDT (Integrated
DNA Technologies, San Diego, CA, USA). Ntera-2.c1D1
(human pluripotent testicular carcinoma/ATCC CRL-1973)
was purchased from American Cell Type Collection (Manas-
sas, VA, USA).
2.1. Human Amniotic Fluid Stem Cells. Human amniotic flu-
id samples were collected during scheduled amniocentesis at
12 to 18 weeks of gestation for diagnosis reasons. Collection
procedure was performed under aseptic conditions using
a 22-gauge needle and under ultrasonographic control.
All samples were obtained after signed informed consent.
The protocol was approved by the Ethics Committee from
University of Sao Paulo School of Medicine, Brazil (no.:
0410-09).
After collection, each sample was centrifuged at 450 × g
for 10min at room temperature. The resulting pellets were
washed with PBS (phosphate buﬀer saline), suspended in
minimal essential medium—α-modification (α-MEM), sup-
plemented with 20% fetal bovine serum, 100UI/mL peni-
cillin, 100 μg/mL streptomycin, and maintained in incubator
with 5% CO2 atmosphere at 37◦C for approximately 12 days,
when the first colonies appeared. The medium was changed
every 3-4 days.
2.2. Growth Curve and Doubling Time. For growth curve,
AFSCs were seeded in 48-well plates (Corning, USA), and
cultivated for 12 days in a platting density of 5,000 cells/cm2.
Cell number was assessed daily in triplicate by trypan blue
staining in hemocytometer (Optik Labor, Friedrichshofen,
Germany) counting. Cell population doubling time was
calculated by the following formula: t = 3, 3 × log(Y/Y0),
where: T : time (hours), Y : final cell number, and Y0: starting
cell number.
2.3. AFSC Undiﬀerentiated Gene Expression by RT-PCR.
To evaluate undiﬀerentiated state of AFSCs, specific gene
expressions were determined: Oct-4 and Nanog. Total RNA
was extracted using Trizol Reagent (Invitrogen, Carlsbad,
CA, USA) according to the manufacturer’s instructions.
Purity of the RNA was assessed by determining the ratio of
absorbance at 260 nm to that at 280 nm. The reactions were
performed with the kit Illustra Ready To Go (GE Healthcare,
Buckinghamshire, UK) in a PTC-200 thermal cycler (MJ
Research Inc., Watertown, USA). Approximately 100 ng of
total RNA were required for reactions.
RT-PCR was performed initially with a step of 50◦C for
30min for reverse transcription of RNA and denaturation
at 95◦C for 5min. This was followed by 35 cycles (94◦C for
30 sec, 57◦C for 30 sec, and 72◦C for 60 sec; final extension
at 72◦C for 8min). All used sense and antisense primers
are described in Table 1. Total RNA from Ntera-2.c1D1 cell
line was used as positive control of undiﬀerentiating state
of AFSCs. Human β-actin gene was used as endogenous
control in all reactions. RT-PCR products were analyzed in
2% agarose gel stained with ethidium bromide and visualized
under ultraviolet light.
2.4. Flow Cytometry Analysis. Specific surface proteins of cul-
tured AFSCs were evaluated by flow cytometry (FacsCalibur
cytometer, Becton Dickinson) and analyzed in CellQuest
software. 1 × 106 cells were trypsinized, washed with PBS,
and stained for 15min in dark room with primary anti-
bodies labeled with fluorochromes FITC (fluorescein isoth-
iocyanate): CD34, CD44, CD45, and CD90; PE (phycoery-
thrin): CD14, CD29, CD105, and appropriate isotype con-
trols (IgG-1, Invitrogen, Caltagaboratories, USA). The num-
ber of acquired events was 20,000 cells in each acquisition.
2.5. Cell Diﬀerentiation Assays. To induce osteogenic dif-
ferentiation, AFSCs at 70–80% confluence were cultured
in osteogenic medium (α-MEM supplemented with 20%
FBS, 10mM glycerol phosphate, 50mM ascorbic acid, and
100 nM dexamethasone) for 3 weeks. The medium was
changed twice weekly. The osteogenic diﬀerentiation was
evaluated by cell staining (Alizarin Red and von Kossa) and
RT-PCR (osteocalcin, osteopontin and Wnt-1 gene expres-
sion).
To induce adipose tissue diﬀerentiation, AFSCs were
treated with adipogenicmedium: α-MEMwith 10−2 uMdex-
amethasone, 0.5mg/mL insulin, 200mM indomethacin and
50mM isobutilmethilxantine for 3 weeks. Medium changes
were carried out twice weekly. Presence of intracellular lipid
droplets, indicative of adipocyte diﬀerentiation, was assessed
by Oil Red O staining. PPAr-γ and lipoprotein lipase gene
expression was determined by RT-PCR.
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Table 1: RT-PCR primer sequences.
Gene Primers PCR products (bp) Tm (◦C)
Oct-4
5′- cgt gaa gct gga gaa gga gaa gct g -3′
5′- caa ggg ccg cag ctt aca cat gtt c-3′
247 61
Nanog
5′-cat gag tgt gga tcc agc ttg-3′
5′-cct gaa taa gca gat cca tgg-3′
191 52
Osteocalcin
5′-atg aga gcc ctc aca ctc ct-3′
5′ caa ggg gaa gag gaa aga ag-3′
359 55
Osteopontin
5′-cat ggc atc acc tgt gcc ata cc-3′
5′-cag tga cca gtt cat cag att cat c-3′
331 57
Wnt-1
5′-cac gac act cgt gca gta cgc-3′
5′-aca gac act cgt gca gta cgc-3′
233 58
Collagen 2A1
5′-cca gga cca aag gga cag aaa g-3′
5′-ttc acc agg ttc acc agg att g-3′
398 57
Perlecan
5′-cat aga gac cgt cac agc aag-3′
5′-atg aac acc aca ctg aca acc-3′
300 55
Syndecan
5′-cct tca cac tcc cca cac-3′
5′-ggc ata gaa ttc ctc ctg ttg-3′
410 54
PPAR-γ 2
5′-gct gtt atg ggt gaa act ctg-3′
5′-ata agg tgg aga tgc agg ctc-3′
351 55
Lipoprotein lipase
5′-cag caa aac ctt ca tggt-3′
5′-agt ttt ggc acc caa ctc tca-3′
72 53
β-actin
5′-tgg cac cac acc ttc tac aat gag c-3′
5′-gca cag ctt ctc ctt aat gtc acg c-3′
396 60
To induce chondrogenic diﬀerentiation, AFSCs were
grown in α-MEM until 80% of confluence was reached. Cells
were trypsinized, transferred to a conical tube, and cen-
trifuged at 450x g for 10min at room temperature. Chondro-
genesis was induced by treating pelleted cells in conical tubes
with α-MEM medium, 10 ng/mL TGF-βI (Calbiochem,
USA) and 100 nM dexamethasone for 3 weeks. Chondro-
genic diﬀerentiation was assessed by hematoxylin and eosin
staining (H&E), immunofluorescence against collagen type
II and RT-PCR (collagen II, perlecan, and syndecan gene
expression).
2.6. Cryopreservation. AFSCs (third passage) were frozen in
the final concentration of 106 cells/mL in freezing medium
(α-MEM 20% FBS plus cryoprotectant), by two diﬀerent
methods. In the nonprogrammed time freezing protocol,
samples were placed in a freezer (−20◦C) for 20min followed
by −80◦C freezing for 12–16 h and, finally, transferred
into liquid nitrogen (N2). Alternatively, programmed time
freezing protocol was used where samples were cooled
in a controlled-rate program (Thermo Forma Scientific,
Minneapolis, USA) of 1◦C/min at −60◦C, then 3◦C/min at
−100◦C followed by liquid N2 storage. The cryoprotectants
used alone were Me2SO (5 and 10%), glycerol (5 and 10%),
sucrose (30 and 60mM), and trehalose (60 and 100mM).
The samples were stored for 3 and 6 months. Thawing was
done quickly in water bath at 37◦C, and then cell viability was
analyzed. Before cell plating all samples were washed with α-
MEMmedium to remove residual cryoprotectant. After 80%
cell confluence was reached, Oct-4 andNanog expression was
evaluated by RT-PCR; CD34, CD45, CD44 (FITC), CD14,
CD29 and CD105 (PE) membrane markers were measured
by flow cytometry; osteogenic and adipogenic diﬀerentia-
tions were performed and confirmed by Alizarin Red and Oil
Red O staining, respectively.
2.7. Statistical Analysis. Data are expressed as mean ± SEM.
One-way or two-way analysis of variance (ANOVA) was
applied to the means to determine statistical diﬀerences be-
tween experimental groups followed by Bonferroni or Dun-
nett’s tests. Diﬀerences betweenmean values were considered
significant when P < 0.05.
3. Results
3.1. AFSCs Isolation and Doubling Time. AFSCs were isolated
of 35 of 41 samples by their adherent properties in plastic
surface and appeared as colonies in the culture flask. They
consisted of fibroblast-like cell morphology. Doubling time
for AFSCs calculated after growth curve was 30 ± 4 h
(Figure 1).
3.2. Cultured AFSCs Express Oct-4 and Nanog. Cultured
AFSCs expressed the transcription factors Oct-4 at diﬀerent
passages, as determined by RT-PCR. Oct-4 is a key marker
expressed in embryonic stem cells and cancer cells and
is responsible for the maintenance of the undiﬀerentiated
state. The homeodomain gene Nanog, present in pluripotent
human cells, was also expressed in cultured AFSCs confirm-
ing the undiﬀerentiated state (Figure 2).
3.3. Phenotypic Characterization of AFSCs by Flow Cytometry.
The results obtained by flow cytometry demonstrated that
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Figure 1: AFSCs growth curve and doubling time. AFSCs (5,000 cells/cm2) were seeded and cultivated in 46-well plates for 12 days. At
the end of each day, cells were washed, trypsinizated, and counted in hemocytometer. Each point refers to triplicate from two diﬀerent AF
samples. Cell doubling time calculated was 30 hours (±4 h).
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Figure 2: Undiﬀerentiated gene expression (Oct-4 and Nanog). AFSCs total RNA was extracted from 3 diﬀerent samples by Trizol method,
gene expression evaluated by RT-PCR, and electrophoresed and visualized under ultraviolet light in 2% agarose gel stained with ethidium
bromide.
stem cells isolated from amniotic fluid have a strong posi-
tivity for mesenchymal markers, such as CD29 (β-integrin),
CD44 (hyaluronic acid receptor), CD90 (Thy-1), and CD105
(endoglin), while they were negative for hematopoietic
markers such as CD14, CD34 and CD45 (leukocyte common
antigen) (Figure 3).
3.4. Diﬀerentiation Properties of AFSCs. AFSCs were cul-
tivated in specific diﬀerentiation medium, as described,
to evaluate their plasticity and multipotency. Osteogenic
diﬀerentiation was confirmed after 21 days by visualization
of the calcium deposits seen with Alizarin Red and von Kossa
staining (Figure 4). Cells also expressed typical genes found
in bone tissue such as osteopontin, osteocalcin, and Wnt-1.
Adipogenic diﬀerentiation was confirmed by Oil Red
O staining. Cytoplasmic lipid droplets appeared stained in
red. They also expressed adipocytes genes as PPAr-γ and
lipoprotein lipase.
AFSCs were also able to diﬀerentiate into chondrogenic
tissue after stimulation with TGF-β I and dexamethasone
for 21 days. Histological sections from treated pellet showed
a typical structure of cartilage tissue. The presence of
collagen type II was detected by immunofluorescence stain-
ing. Diﬀerentiated cells expressed genes typically found in
condroblasts, such as syndecan, perlecan and collagen type II
(Figure 4).
3.5. Cryopreservation. AFSCs viability after thawing did not
present statistical diﬀerence when compared the nonpro-
grammed and programmed time freezing protocols after 3
and 6 months storage (Figure 5).
All evaluated cryoprotectants preserved the basic features
of AFSCs, as Oct-4 and Nanog genes expression (Figure 6),
surface markers (CD29, CD44, and CD105 positive; CD14,
CD34, and CD45 negative, Tables 2 and 3) and diﬀeren-
tiation multipotential after thawing (Figure 7). Although,
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Figure 3: AFSCs membrane proteins were evaluated by flow cytometry with CellQuest software. Acquisitions were shown in histograms.
AFSCs were positive for CD29 (98.27 ± 1.23%), CD44 (98.28 ± 1.65%), CD90 (97.69 ± 1.84%), CD105 (98.77 ± 0.64%) and were negative
for CD14 (1.78 ± 1.06%), CD34 (1.70 ± 1.14%), and CD45 (1.80 ± 0.74%). IgG1-FITC and IgG1-PE antibodies were utilized as isotype
controls. The number of acquired events was 20,000 in each acquisition.
Me2SO (5 and 10%) and glycerol (5 and 10%) showed higher
rates of viability than the extracellular cryoprotectants, su-
crose and trehalose (Figure 8).
4. Discussion
The interest of mesenchymal stem cells in the scientific
community has arisen due to their peculiar characteristics.
Among them, the highlights are proliferative capacity and
diﬀerentiation potential [16–18]. Human amniotic fluid
from second trimester of pregnancy was appointed recently
as an alternative source for MSCs [19, 20]; however, some
features, especially about cryopreservation analysis, are not
fully described. In the present study, we isolated AFSCs
and examined two freezing protocols as well as distinct
cryoprotectants which could maintain high viability and
stemness of AFSCs after cryopreservation.
Primary culture of human amniotic fluid revealed the
presence of fibroblast-like cells capable of adhesion and
colonies formation in plastic dish surface. These cells were
classified as mesenchymal stem cells by their characteristics,
as follows.
AFSCs doubling time (30 hours) founded was similar
with that described elsewhere [21], and this demonstrated
the high proliferative potential of these cells.
Key gene expression profile, such as Oct-4 and Nanog, is
essential to determine the undiﬀerentiated stem cells status.
These genes are commonly found in pluripotent stem cells
and cancer cells [22]. Specific surface markers were investi-
gated using a panel of membrane antibodies that virtually
exclude the presence of contaminating hematopoietic cells
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Figure 4: AFSCs plasticity. AFSCs were seeded in 6-well plates and cultivated with osteogenic, adipogenic, and chondrogenic inductor
medium for 3 weeks. (a) Control cells cultivated without inductor medium (magnification: 40x). (b) Osteogenic diﬀerentiation was assessed
by von Kossa (calcium deposits in black) and (c) Alizarin Red (calcium deposits in red) staining. Adipogenic diﬀerentiation was assessed by
Oil Red O staining. (d) Diﬀerentiated cells without staining (magnification: 40x), (e) diﬀerentiated cells stained by Oil Red O (cytoplasmic
lipids droplets in red, 400x). (f) Chondrogenic diﬀerentiation was confirmed with H&E (magnification: 400x) (g) and immunofluorescence
staining with antibodies against collagen type II (400x). (h) Osteogenic gene expression was determined by RT-PCR; products were
electrophorezed and visualized under ultraviolet light in 2% agarose gel stained with ethidium bromide (100 bp molecular weight, control
(water), osteopontin [OPN], osteocalcin [OCN] and Wnt-1). (i) Typical adipogenic gene expression was determined by RT-PCR (100 bp
molecular weight, control (water), PPAr-γ and lipoprotein lipase). (j) Chondrogenic gene expression was determined by RT-PCR (100 bp
molecular weight, control (water), collagen type II, perlecan, and syndecan).
Table 2: After nonprogrammed freezing, AFSCs (n = 5) maintained their specific mesenchymal membrane proteins evaluated by flow
cytometry (CD29, CD44, and CD105 positive; CD14, CD34, and CD45 negative). The number of acquired events was 15,000 in each acqui-
sition. Results are shown as percentage ±SEM.
Nonprogrammed CD14 PE CD34 FITC CD45 FITC CD29 PE CD44 FITC CD105 PE
Me2SO 5% 1.22 ± 0.25 0.29 ± 0.25 0.35 ± 0.16 98.30 ± 1.05 99.26 ± 0.39 99.01 ± 1.03
Me2SO 10% 1.02 ± 0.18 0.74 ± 0.22 5.80 ± 2.02 99.81 ± 0.11 99.90 ± 0.07 99.26 ± 0.36
Glycerol 5% 0.94 ± 0.44 0.44 ± 0.16 0.84 ± 0.31 99.54 ± 0.26 99.91 ± 0.06 98.92 ± 0.95
Glycerol 10% 0.87 ± 0.56 0.09 ± 0.27 0.16 ± 0.09 99.10 ± 0.33 99.09 ± 0.46 99.33 ± 0.51
Sucrose 30mM 1.06 ± 0.23 0.81 ± 0.51 1.08 ± 0.73 99.74 ± 0.04 99.69 ± 0.18 99.44 ± 0.12
Sucrose 60mM 0.95 ± 0.65 1.14 ± 0.89 3.49 ± 0.88 99.43 ± 0.25 99.57 ± 0.32 98. 26 ± 1.39
Trehalose 60mM 1.93 ± 0.26 0.36 ± 0.31 0.37 ± 0.26 99.86 ± 0.28 99.98 ± 0.01 98.24 ± 1.17
Trehalose 100mM 0.82 ± 0.72 0.48 ± 0.28 0.79 ± 0.17 99.91 ± 0.05 99.08 ± 0.74 99.54 ± 0.09
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Figure 5: AFSCs viability comparing nonprogrammed and programmed freezing protocols. we did not have statistic diﬀerences in AFSCs
viability when we compared the two freezing methods tested. (a) AFSCs viability after 6 months in programmed and nonprogrammed
freezing using diﬀerent cryoprotectants. (b) AFSCs viability after 3 months in programmed and nonprogrammed freezing using diﬀerent
cryoprotectants. M-Me2SO, G-glycerol, S-sucroses and T-trehalose. Means were compared by one-way ANOVA Dunnett posttest (∗P <
0.05).
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Figure 6: AFSCs were thawed, total RNA was extracted, and Oct-4 and Nanog gene expression was determined by RT-PCR in 2% agarose
gel stained with ethidium bromide after freezing with diﬀerent cryoprotectants. Human β-actin was used as endogenous control. MW:
100 bp molecular weight; A: 5% Me2SO nonprogrammed; B: 5% Me2SO, programmed; C: 10% Me2SO, nonprogrammed; D: 10% Me2SO,
programmed; E: 5% Glycerol, nonprogrammed; F: 5% Glycerol, programmed; G: 10% Glycerol, nonprogrammed; H: 10% Glycerol,
programmed; I: 30mM Sucrose, nonprogrammed; J: 30mM Sucrose, programmed; K: 60mM Sucrose, nonprogrammed; L: 60mM Sucrose,
programmed; M: 60mM Trehalose, nonprogrammed; N: 60mM Trehalose, programmed; O: 100mM Trehalose, nonprogrammed; P:
100mM Trehalose; programmed; Q: positive control (Ntera-2.c1D1 cell line).
Table 3: After programmed freezing, AFSCs (n = 5)maintained their specificmesenchymal membrane proteins evaluated by flow cytometry
(CD29, CD44, and CD105 positive; CD14, CD34, and CD45 negative). The number of acquired events was 15,000 in each acquisition. Results
are shown as percentage ±SEM.
Programmed CD14 PE CD34 FITC CD45 FITC CD29 PE CD44 FITC CD105 PE
Me2SO 5% 1.88 ± 0.35 0.58 ± 0.22 0.85 ± 0.53 96.06 ± 2.61 97.03 ± 2.06 98.82 ± 1.06
Me2SO 10% 0.92 ± 0.46 0.75 ± 0.13 0.76 ± 0.44 99.67 ± 0.16 99.88 ± 0.10 99.02 ± 0.15
Glycerol 5% 0.91 ± 0.74 0.18 ± 0.08 0.39 ± 0.29 99.48 ± 0.40 99.85 ± 0.16 99.51 ± 0.17
Glycerol 10% 1.76 ± 0.96 1.07 ± 0.97 1.12 ± 1.01 99.71 ± 0.16 99.87 ± 0.08 99.11 ± 0.39
Sucrose 30mM 0.62 ± 0.48 0.22 ± 0.14 0.48 ± 0.15 99.29 ± 0.19 99.95 ± 0.03 99.65 ± 0.06
Sucrose 60mM 1.36 ± 0.08 0.96 ± 0.06 1.51 ± 0.83 99.35 ± 0.28 99.17 ± 0.66 99.02 ± 0.20
Trehalose 60mM 1.25 ± 0.41 0.31 ± 0.25 0.48 ± 0.25 97.77 ± 1.31 99.85 ± 0.11 98.90 ± 0.66
Trehalose 100mM 0.53 ± 0.88 0.46 ± 0.36 0.60 ± 0.56 99.50 ± 0.36 99.83 ± 0.18 98.94 ± 0.76
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Figure 7: After thawing, AFSCs freezed with diﬀerent cryoprotectants ((b)Me2SO, (c) glycerol, (d) sucrose, and (e) trehalose) were cultivated
with osteogenic and adipogenic inductor medium. Diﬀerentiation was confirmed by Alizarin Red and Oil Red O staining after 21 days.
(a) Control cells without inductor. Calcium deposits appear in red. All cryoprotectants tested maintained osteogenic and adipogenic
diﬀerentiation potential of AFSCs after storage for 6 months.
and examined proteins commonly present in MSCs, as CD29
(β-integrin), CD44 (hyaluronic acid receptor), CD90 (Thy-
1) and CD105 (endoglin). Data also showed the high diﬀer-
entiation potential of the AFSCs in osteogenic, adipogenic,
and chondrogenic lineages, thus confirming their multipo-
tent state.
Cell cultures require cooling methods for long-time
storage, and the choice of freezing protocol used must be
done carefully to avoid cell death and, mainly, to maintain
the cell characteristics, as in this case, AFSCs proliferation
and plasticity properties [23]. With this aim our study
compared two freezing protocols: a programmed-rate cool-
ing and, a more conventional approach, nonprogrammed
time freezing, both with subsequent storage in liquid ni-
trogen.
The cooling rate is a critical step during freezing. If
cooling is suﬃciently slow, the cell is able to lose water rapidly
enough by exosmosis to concentrate the intracellular solutes
suﬃciently to eliminate supercooling and maintain the
chemical potential of intracellular water in equilibrium
with that of extracellular water. The result is that the cell
dehydrates and does not freeze intracellularly. But if the cell is
cooled too rapidly, it is not able to lose water fast enough to
maintain equilibrium; it becomes increasingly supercooled
and eventually attains equilibrium by freezing intracellularly.
Intracellular ice formation leads to cell death [2].
It was observed that the two methods had no eﬀect
when compared with each other in cellular viability after
thawing. Therefore, a nonprogrammedmethod should make
cryopreservation more convenient and less costly because
the use of complex equipment for controlled-rate freezing is
avoided.
Cryoprotectants are essential tomaintain the cell viability
and function for storage at very low temperatures, including
for amniotic fluid-derived stem cells [24, 25]. In this study,
diﬀerent cryoprotectants were tested, two intracellular com-
pounds that impair crystal ice formation inside the cells
(Me2SO and glycerol) and two extracellular agents which
improve freezing osmotic imbalance (sucrose and trehalose).
Me2SO is the most widely used cryoprotectant [21, 26],
but several studies report their potential to induce neuronal
diﬀerentiation in stem cells [5, 27]. This fact together with
their cell toxicity in room temperature led us to search for
other cryoprotectants to use for freezing AFSCs. Neuronal
diﬀerentiation promoted by Me2SO was not observed in our
study since cells were washed with α-MEM medium right
after thawing, eliminating any trace of the cryoprotectant.
Therefore, AFSCs frozen with Me2SO kept their Oct-4 and
Nanog genes expression and diﬀerentiation capacity.
Glycerol, another intracellular cryoprotectant, was com-
pared with Me2SO. Glycerol is also widely used in concentra-
tions of 5 and 10%, in cell cultures. It is described that it does
not promote cellular toxicity [28], but its action in AFSCs
cryopreservation has not been described so far. Glycerol,
both at 5 and 10% has caused lower viability than Me2SO,
but yet in acceptable rates for cell culture.
Disaccharides such as sucrose and trehalose have also
been widely used as natural cryoprotectants, as excipients
for freeze drying and as stabilizers during dehydration. The
precise mechanism by which disaccharides act to preserve
biological systems during freezing and drying is not well
understood. The fact that they do not enter in cells is the
main advantage, facilitating their removal after thawing [29].
Sucrose and trehalose led to a low rate of AFSCs viability
and, consequently, an increase in lag phase after thawing,
maybe because these extracellular agents do not prevent the
formation of ice crystals within the cell.
All tested cryoprotectants maintained the Oct-4 and
Nanog gene expression and did not alter membrane markers
Journal of Biomedicine and Biotechnology 9
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Figure 8: AFSCs viability comparing diﬀerent cryoprotectants (Me2SO, glycerol, sucrose, and trehalose) and programmed and nonpro-
grammed freezing protocols after 3 and 6 months. (a) viability in nonprogrammed method for 3 months; (b) viability in programmed
method for 3 months; (c) viability in nonprogrammed method for 6 months; (d) viability in programmed method for 6 months. 10%
Me2SO showed the higher viability rate similar to NR control in all cases. NR-AFSCs viability control measured before freezing procedure.
M-Me2SO, G-glycerol, S-sucrose, and T-trehalose. Means were compared by one-way ANOVA Dunnett’s (∗∗∗P < 0.05) and Bonferroni
(#P < 0, 05) post tests.
or the plasticity of AFSCs post thawing, which were able to
diﬀerentiate into bone and fat tissues after thawing.
5. Conclusions
Human amniotic fluid collected in the second trimester of
gestation contains mesenchymal stem cells which show a
high rate of proliferation in vitro and multipotent profile,
as shown by histological and gene expression studies. Both,
nonprogrammed and programmed time freezing methods,
could be used for AFSCs cryopreservation for 6 months.
Although all tested cryoprotectants maintained Oct-4 and
Nanog gene expression, typical surface markers, and mul-
tilineage diﬀerentiation of AFSCs, only Me2SO and glycerol
presented workable viability ratio.
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